Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass

Background: Ivacaftor, the first CFTR modulator drug, leads to significant long-term improvement in lung function and weight gain. The mechanism as well as the long-term impact of ivacaftor on weight, resting energy expenditure (REE) and body composition remains to be explored. Methods: This prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouzaki, Marialena, Dupuis, Annie, Avolio, Julie, Griffin, Katherine, Ratjen, Felix, Tullis, Elizabeth, Gonska, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372433/
https://www.ncbi.nlm.nih.gov/pubmed/37521467
http://dx.doi.org/10.3389/fphar.2023.1157459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372433/
https://www.ncbi.nlm.nih.gov/pubmed/37521467
http://dx.doi.org/10.3389/fphar.2023.1157459

Ejemplares similares